This clinical trial is focused on studying a type of lung cancer known as Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC). The study is comparing two treatments: a new medication called Datopotamab deruxtecan (also known by its code name DS-1062a) and an existing chemotherapy drug called Docetaxel. Both medications are given through an intravenous infusion, which means they are delivered directly into the bloodstream through a vein.

The purpose of the study is to see how well DS-1062a works compared to Docetaxel in patients who have already received treatment for their lung cancer. Participants in the study will be randomly assigned to receive either DS-1062a or Docetaxel. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of the treatments. The study will last for a period of up to 72 weeks, during which time participants will receive regular infusions and have their health monitored closely by the study team.

Throughout the study, participants will undergo various assessments to track the progress of their cancer and overall health. These assessments may include imaging tests to look at the size and spread of the cancer, as well as regular check-ups to monitor any side effects from the treatments. The goal is to determine which treatment is more effective in controlling the cancer and improving the quality of life for patients with NSCLC.